Naldemedine

Symproic, Rizmoic (naldemedine) is a small molecule pharmaceutical. Naldemedine was first approved as Symproic on 2017-03-23. It is used to treat constipation in the USA. It has been approved in Europe to treat constipation. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target delta-type opioid receptor. Symproic's patents are valid until 2033-05-13 (FDA).